Eli Lilly Stock Up 36% This Year — Why the Weight-Loss Drug Company Is Also Becoming an AI Investment

Eli Lilly has spent the last several years becoming one of the most successful pharmaceutical companies in history almost entirely on the strength of two drugs. Mounjaro and Zepbound, both built on a class of medicine called GLP-1 receptor agonists, have turned the Indianapolis-based company into the dominant force in diabetes and weight-loss treatment, and the financial results have been extraordinary. But buried inside Lilly's recent earnings reports and corporate announcements is a second story that has received far less attention from casual investors, even though it could shape the company's next decade just as much as its weight-loss franchise has shaped this one. Eli Lilly is quietly assembling one of the most serious artificial intelligence drug discovery operations in the pharmaceutical industry, and the company increasingly wants to be understood not just as a weight-loss drug maker, but as an AI-powered medicine factory.

For investors, that combination, a wildly profitable existing business stacked on top of an aggressive AI bet, helps explain why Lilly's stock has climbed roughly 36% so far this year, even as the broader market has had a far more uneven run. Understanding both halves of that story, the GLP-1 boom that is happening now and the AI strategy that is meant to keep the growth going for years to come, is the key to understanding why Wall Street has been willing to pay such a high price for Lilly shares.

The Numbers Behind the Rally

Eli Lilly's first-quarter 2026 results, released at the end of April, were the kind of figures that make analysts stop and recheck their math. Worldwide revenue came in at $19.8 billion, an increase of 56% compared with the same quarter a year earlier, driven primarily by a 65% increase in sales volume that was only partially offset by lower realized prices. Net income on a reported basis surged 168% to $7.4 billion, while earnings per share jumped 170% to $8.26. Mounjaro alone generated $8.7 billion in the quarter, more than double what it produced a year earlier, while Zepbound's global revenue climbed to roughly $4.2 billion, up 83% year over year.

These are not numbers that typically describe a mature pharmaceutical company. Lilly's operating income jumped 141% in the quarter, and the company was confident enough in its momentum to raise its full-year 2026 revenue guidance to a range of $82 billion to $85 billion, representing roughly 28% growth at the midpoint, alongside raised earnings guidance as well. With the stock trading near $1,120 a share and the company carrying a market capitalization north of $1 trillion, Lilly has become one of the largest and most richly valued healthcare companies in the world, and the market has rewarded that performance with a share price that touched an all-time high above $1,180 earlier in June.

Foundayo: The Pill That Could Reshape the Weight-Loss Market

A meaningful part of the optimism behind Lilly's current valuation rests on a single regulatory milestone that arrived alongside the first-quarter results. In April 2026, the FDA approved Foundayo, known chemically as orforglipron, making it the first oral GLP-1 medication launched specifically for obesity. Every other major GLP-1 weight-loss treatment on the market, including Lilly's own Zepbound and Novo Nordisk's Wegovy, requires a weekly injection. Foundayo's arrival as a once-daily pill removes one of the biggest practical barriers that has kept some patients away from GLP-1 treatment altogether, whether out of discomfort with needles, logistical difficulty, or simple preference.

The strategic importance of this approval is difficult to overstate. The injectable GLP-1 market has already proven to be enormous, but a convenient oral alternative opens the door to a much larger population of patients, including those managing diabetes or obesity who have specifically avoided injectable treatments. Lilly has paired the Foundayo launch with broad pharmacy and telehealth availability, and alongside it introduced an Employer Connect program and a Medicare GLP-1 Bridge initiative designed to expand affordable access, including capping out-of-pocket costs for some Medicare patients at $50 a month. If Foundayo performs the way Lilly's internal projections suggest, it could become one of the most commercially significant pharmaceutical launches in years, extending the company's dominance in metabolic disease well beyond what injectable treatments alone could achieve.

Why Lilly Is Betting Big on Artificial Intelligence

Here is where Lilly's story becomes more interesting than a simple account of weight-loss drug demand. In March 2026, Lilly announced a significant expansion of its relationship with Insilico Medicine, a Hong Kong-listed biotechnology company specializing in AI-driven drug discovery. Under the terms of the deal, Insilico will receive $115 million upfront, with potential development, regulatory and commercial milestone payments bringing the total value of the collaboration to approximately $2.75 billion, plus tiered royalties on any resulting products that reach the market. In exchange, Lilly secures exclusive worldwide rights to develop, manufacture and commercialize a portfolio of preclinical-stage oral small-molecule therapeutics generated using Insilico's generative AI drug discovery platform, with the two companies also running additional joint discovery programs on targets that Lilly selects.

This is not Lilly's first move into AI-assisted drug discovery, and that history matters for understanding how seriously the company is taking this shift. The relationship with Insilico actually began back in 2023 with a smaller software licensing arrangement, before deepening into a $100 million partnership in November 2025 and now this far larger collaboration. In parallel, Lilly partnered with Nvidia in October 2025 to build what the companies described as the most powerful supercomputer ever owned and operated by a pharmaceutical company, a system the company has since branded LillyPod. Built using more than 1,000 Nvidia Blackwell GPUs, LillyPod is designed to train foundation models across drug discovery, genomics and clinical development workflows, effectively giving Lilly the kind of dedicated computing infrastructure that, until recently, was associated almost exclusively with major technology companies rather than pharmaceutical manufacturers.

Lilly has also built TuneLab, a federated AI platform that gives external biotechnology partners access to Lilly's own models, which have been trained on more than $1 billion worth of proprietary drug discovery data spanning preclinical research, safety profiles, and molecular optimization datasets. Thomas Fuchs, Lilly's chief AI officer, has described the company's broader philosophy in a way that captures the scale of the ambition: Lilly's goal is to shift from treating AI as a tool that occasionally assists scientists toward embracing it as a genuine scientific collaborator embedded throughout the entire drug discovery and development process.

What Owning Both Businesses Actually Means

Putting these two halves of Lilly's strategy side by side reveals something genuinely distinctive about where the company is positioning itself. On one side, Lilly already dominates the most commercially successful new drug category in a generation, with Mounjaro, Zepbound and now Foundayo giving it leadership across injectable and oral treatment options for both diabetes and obesity. On the other side, the company is assembling AI infrastructure, proprietary datasets and external partnerships at a scale that few, if any, other pharmaceutical companies have matched, positioning itself to discover and develop the next generation of medicines faster and more efficiently than rivals relying primarily on traditional research methods.

The logic connecting these two strategies is straightforward even if the execution is difficult. The revenue and profit generated by Mounjaro, Zepbound and Foundayo give Lilly an extraordinary amount of capital to deploy, and rather than simply returning all of that capital to shareholders or pursuing conventional acquisitions, the company has chosen to reinvest heavily in AI infrastructure and AI-native drug discovery partnerships. If that bet pays off, Lilly would not just be the company that won the GLP-1 era. It would be the pharmaceutical company best positioned to identify and develop whatever comes after GLP-1 drugs, using AI to compress the years of trial-and-error that traditionally define early-stage drug discovery into a faster, more systematic process.

It is worth being honest about the uncertainty here as well. AI-driven drug discovery has generated enormous excitement across the pharmaceutical industry, including from competitors like Pfizer, Novartis, Bristol Myers Squibb and AstraZeneca, but the technology has not yet produced the kind of definitive, widely recognized clinical breakthroughs that would prove the approach decisively works at scale. Generative AI models can propose promising drug candidates rapidly, but those candidates still have to survive the same lengthy, expensive and uncertain clinical trial process that has always determined whether a new medicine actually succeeds. Lilly's AI strategy is best understood as a well-funded, well-resourced bet on a promising approach, not as a guaranteed pipeline of future blockbuster drugs.

What This Means for Investors

For anyone considering Lilly stock at its current price, the investment case ultimately rests on believing two separate things simultaneously. The first is that the GLP-1 market still has substantial room to grow, with Foundayo's oral convenience and Lilly's continued international expansion likely to keep driving the kind of revenue growth that has defined the last several years. The second, more speculative belief is that Lilly's AI investments, anchored by LillyPod, TuneLab and the expanded Insilico partnership, will translate into a genuine and durable advantage in discovering new medicines faster than competitors relying on more traditional research and development processes.

The first belief is supported by hard, already-realized financial results. The second belief is a forward-looking wager on a technology that remains unproven at the scale Lilly is now committing to it. A stock trading near $1,120 a share, with a market capitalization above $1 trillion and a price-to-earnings ratio in the high thirties, already reflects substantial optimism about both stories continuing to play out successfully. That does not make Lilly a bad investment, but it does mean that investors buying in now are paying for a great deal of future success that has not yet been demonstrated, on top of a weight-loss drug business that, while genuinely excellent, also faces growing competition from Novo Nordisk and a widening field of newer entrants developing their own GLP-1 and next-generation metabolic treatments.

The Bottom Line

Eli Lilly's 36% stock gain this year tells a story that is, on the surface, about extraordinary demand for weight-loss and diabetes medication. Underneath that story, though, is a second, less visible transformation in which one of the world's largest pharmaceutical companies is methodically building the AI infrastructure, data assets and research partnerships needed to discover its next generation of blockbuster drugs more quickly than its competitors. Both stories are real, and both are reflected in the company's soaring valuation. Whether that valuation continues to make sense will depend less on how Mounjaro and Foundayo perform over the next year, where the trends already look favorable, and more on whether Lilly's enormous bet on artificial intelligence as a genuine scientific collaborator actually produces the kind of breakthrough medicines that would justify treating Eli Lilly as seriously as an AI company as it is already treated as a pharmaceutical one.

*This article is for informational purposes only and does not constitute financial or investment advice. Always conduct your own research or consult a licensed financial advisor before making investment decisions. Data referenced is sourced from Eli Lilly's SEC filings and investor relations releases, BioSpace, Fierce Biotech, Pharmaceutical Technology, and BioPharma Trend as of June 2026.*